Bell Investment Advisors’s Ginkgo Bioworks DNA Stock Holding History

Bell Investment Advisors’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-65	Closed	-$948	–	1836
2025 Q3	$948	Hold	65	–	–	﹤0.01%	1568
2025 Q2	$732	Buy	65 +58	+829%	+$449	﹤0.01%	1679
2025 Q1	$40	Hold	7	–	–	﹤0.01%	1894
2024 Q4	$69	Hold	7	–	–	﹤0.01%	1890
2024 Q3	$58	Sell	7 -1	-13%	-$10	﹤0.01%	1871
2024 Q2	$106	Hold	8	–	–	﹤0.01%	1931
2024 Q1	$367	Sell	8 -10	-56%	-$518	﹤0.01%	1876
2023 Q4	$1.21K	Sell	18 -51	-74%	-$3.12K	﹤0.01%	1531
2023 Q3	$5.01K	Sell	69 -3	-4%	-$240	﹤0.01%	803
2023 Q2	$5.38K	Buy	72 +1	+1%	+$59	﹤0.01%	784
2023 Q1	$3.77K	Sell	71 -7	-9%	-$444	﹤0.01%	924
2022 Q4	$5.26K	Buy	78 +25	+47%	+$2.3K	﹤0.01%	782
2022 Q3	$7K	Buy	53 +31	+141%	+$3.69K	﹤0.01%	529
2022 Q2	$2K	Buy	+22	New	+$2.68K	﹤0.01%	1126

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bell Investment Advisors's DNA Position: Q4 2025 in Review

Bell Investment Advisors sold out of Ginkgo Bioworks (DNA) in Q4 2025, closing a stake of 65 shares — an estimated $948 sold.

Bell Investment Advisors first reported a position in DNA in Q2 2022 and held it in 14 quarters. The position peaked at $7K in Q3 2022. 181 funds tracked by Wall St. Rank hold DNA as of Q4 2025.

Bell Investment Advisors reported no remaining Ginkgo Bioworks position as of Q4 2025 after selling out during the quarter.
Bell Investment Advisors sold 65 Ginkgo Bioworks shares in Q4 2025, an estimated $948.
Bell Investment Advisors first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 14 quarters.
Bell Investment Advisors's Ginkgo Bioworks position peaked at $7K in Q3 2022.
181 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2025.

Based on Bell Investment Advisors's 13F filing for Q4 2025, filed 24 Feb 2026.